Protagonist Therapeutics, Inc.
7707 Gateway Boulevard
Suite 140
Newark
California
94560
United States
Tel: 650-587-5766
Fax: n./a
Website: http://www.protagonist-inc.com/
Email: info@protagonist-inc.com
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Its primary focus is on developing first-in-class oral peptide drugs that specifically target biological pathways also targeted by currently marketed injectable antibody drugs. Compared to injectable antibody drugs, Protagonist's oral peptides offer targeted delivery to the gastrointestinal (GI) tissue compartment, potential for improved safety due to minimal exposure in the blood, improved convenience and compliance due to oral delivery, lower cost, and an opportunity for earlier introduction of targeted therapy for inflammatory bowel disease (IBD). Protagonist's initial lead product candidates, PTG-100 and PTG-200, are based on this approach, and the company believes they have the potential to transform the existing treatment paradigm for IBD, a GI disease consisting primarily of ulcerative colitis and Crohn's disease.
YEAR FOUNDED:
2001
LEADERSHIP:
Founder: Mark Symythe
CEO: Dinesh Patel
CMO (Marketing): Richard Shames
CFO: Tom O’Neil
CSO (Scientific): David Liu
JOBS:
Please click here for Protagonist Therapeutics job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
211 articles about Protagonist Therapeutics, Inc.
-
Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology Summit
12/1/2022
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will participate in a fireside chat presentation and host one-on-one meetings with investors at the JMP Securities Hematology and Oncology Summit, a virtual investor event taking place December 6-7, 2022.
-
Protagonist Therapeutics Reports Granting of Inducement Award - November 16, 2022
11/16/2022
Protagonist Therapeutics, Inc. reported that on November 15, 2022, it issued inducement awards to Arturo Molina, M.D., M.S., F.A.C.P., the Company's recently hired Chief Medical Officer, in accordance with the terms of Dr. Molina's employment offer letter.
-
Protagonist Reports Third Quarter 2022 Financial Results and Provides Corporate Update
11/8/2022
Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
-
Protagonist Therapeutics Announces Poster Presentations at the American Society of Hematology 2022 Annual Meeting
11/3/2022
Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") announced today that three abstracts related to the Company's rusfertide program have been accepted as poster presentations at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH), taking place December 10-13, 2022 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
-
Protagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P. as Chief Medical Officer
11/2/2022
Protagonist Therapeutics announced the appointment of Arturo Molina, M.D., M.S., F.A.C.P. to the role of Chief Medical Officer, effective November 7, 2022.
-
Protagonist Therapeutics Reports Granting of Inducement Award - September 20, 2022
9/20/2022
Protagonist Therapeutics, Inc. reported that on September 15, 2022, it issued an inducement award to Pedro Oyuela, M.D., the Company's recently hired Vice President of Pharmacovigilance, in accordance with the terms of Dr. Oyuela's employment offer letter.
-
Protagonist Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8/4/2022
Protagonist Therapeutics reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.
-
Protagonist Therapeutics Reports Granting of Inducement Award - July 19, 2022
7/19/2022
Protagonist Therapeutics, Inc. reported that on July 15, 2022, it issued an inducement award to Karen Peterson, the Company's recently hired Vice President, Controller, in accordance with the terms of Ms. Peterson's employment offer letter.
-
Protagonist Therapeutics to Participate at the Jefferies Healthcare Conference - June 01, 2022
6/1/2022
Protagonist Therapeutics, Inc. announced that Dinesh V. Patel, Ph.D., President, and Chief Executive Officer, will present at the Jefferies Healthcare Conference in New York on Wednesday, June 8 at 9:30 a.m. ET.
-
Protagonist Therapeutics announced updated promising data from its phase II Revive clinical trial, which is evaluating the safety and efficacy of rusfertide in patients with polycythemia vera (PV).
-
Protagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022
5/26/2022
Protagonist Therapeutics (Nasdaq: PTGX) today announced new data from its ongoing Phase 2 REVIVE study evaluating rusfertide in patients with polycythemia vera (PV).
-
Protagonist Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/4/2022
Protagonist Therapeutics reported financial results for the first quarter of 2022 ended March 31, 2022 and provided a corporate update.
-
A roundup of last week's top clinical trial updates and news.
-
Protagonist Therapeutics' Phase II study of an ulcerative colitis treatment failed to meet its primary endpoint at a higher dosage amount. Even so, the company remains optimistic about the drug's future.
-
Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis
4/25/2022
Protagonist Therapeutics (Nasdaq: PTGX) today announced topline results from the Phase 2 IDEAL study evaluating PN-943 in patients with moderate-to-severe ulcerative colitis (UC).
-
Protagonist Therapeutics Reports Granting of Inducement Awards - Apr 19, 2022
4/19/2022
Protagonist Therapeutics, Inc. reported that on April 18, 2022, it issued inducement awards to three recently hired employees in accordance with the terms of their employment offer letters.
-
Protagonist disclosed the FDA issued a letter of intent to rescind the status for rusfertide based on concerns first raised in a clinical hold placed on the drug.
-
Protagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President and Chief Financial Officer
3/28/2022
Protagonist Therapeutics (Nasdaq: PTGX) today announced the appointment of Asif Ali as Executive Vice President and Chief Financial Officer (CFO).
-
Protagonist Therapeutics Earns $25 Million Milestone Payment from Janssen Biotech for Dosing of Third Patient in Phase 2b Clinical Trial of PN-235 in Moderate-to-Severe Plaque Psoriasis
3/16/2022
Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") announced today earning a $25 million milestone payment from its collaboration with Janssen Biotech, Inc.
-
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
2/28/2022
Protagonist Therapeutics reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.